An early morning press release from BioDelivery Sciences (BDSI) announced that the ongoing BEMA Buprenorphine Phase III trial is more than 50% enrolled and is expected to be completed on schedule.
The trial, measuring BEMA Bup for effectiveness in treating chronic pain, began in December of last year, and is scheduled to wrap-up later this year, with an expected NDA filing to take place during the first half of
Complete Story »
Gina Philips Jamie Gunns Ananda Lewis Kate Bosworth Tamala Jones
No comments:
Post a Comment